Zorifertinib

A tyrosine kinase inhibitor used in cancer treatment

Zorifertinib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Zorifertinib is a tyrosine kinase inhibitor (TKI) that is primarily used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC). It is designed to target specific mutations in the epidermal growth factor receptor (EGFR) gene, which are often implicated in the development and progression of cancer.

Mechanism of Action

Zorifertinib functions by inhibiting the activity of the epidermal growth factor receptor (EGFR), a protein that, when mutated, can promote the growth and spread of cancer cells. By blocking the tyrosine kinase activity of EGFR, zorifertinib disrupts the signaling pathways that lead to tumor growth and survival.

Clinical Use

Zorifertinib is primarily indicated for the treatment of patients with non-small cell lung cancer (NSCLC) that harbor specific EGFR mutations. These mutations are often found in patients who have never smoked or have a history of light smoking. The drug is administered orally and is part of a class of targeted therapies that aim to treat cancer by interfering with specific molecular targets involved in tumor growth.

Side Effects

Common side effects of zorifertinib include diarrhea, rash, nausea, and fatigue. More serious adverse effects can include interstitial lung disease, hepatotoxicity, and severe skin reactions. Patients undergoing treatment with zorifertinib require regular monitoring to manage these potential side effects effectively.

Development and Approval

Zorifertinib was developed as part of ongoing efforts to create more effective targeted therapies for cancer. It was approved for use after clinical trials demonstrated its efficacy in patients with specific EGFR mutations. The approval process involved rigorous testing to ensure the drug's safety and effectiveness in the target patient population.

Research and Future Directions

Ongoing research is focused on understanding the full potential of zorifertinib in treating other types of cancer and in combination with other therapies. Studies are also exploring mechanisms of resistance that may develop during treatment and strategies to overcome them.

Related Pages

• Epidermal growth factor receptor
• Non-small cell lung cancer
• Tyrosine kinase inhibitor
• Targeted therapy